Strong protection against ricin challenge induced by a novel modified ricin A-chain protein in mouse model

References

• Lord JM, Roberts LM, Robertus JD. Ricin: structure, mode of action, and some current applications. FASEB J 1994; 8:201-8; PMID:8119491
   PubMed Web of Science ®Google Scholar
• Endo Y, Mitsui K, Motizuki M, Tsurugi K. The mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes. The site and the characteristics of the modification in 28 S ribosomal RNA caused by the toxins. J Biol Chem 1987; 262:5908-12; PMID:3571242
   PubMed Web of Science ®Google Scholar
• Zhou XX, Ji F, Zhao JL, Cheng LF, Xu CF. Anti-cancer activity of anti-p185HER-2 ricin A chain immunotoxin on gastric cancer cells. J Gastroenterol Hepatol 2010; 25:1266-75; PMID:20594254; http://dx.doi.org/10.1111/j.1440-1746.2010.06287.x
   PubMed Web of Science ®Google Scholar
• Zhang XJ, Ke LM, Yang J, Lin LW, Xue ES, Wang Y, Yu LY, Chen ZK. Development, characterization and anti-tumor effect of a sequential sustained-release preparation containing ricin and cobra venom cytotoxin. Pharmazie 2012; 67:618-21; PMID:22888519
   PubMed Web of Science ®Google Scholar
• Liao P, Liu W, Li H, Gao H, Wang H, Li N, Sun Y. Morphological changes of ricin toxin-induced apoptosis in human cervical cancer cells. Toxicol Ind Health 2012; 28:439-48; PMID:21937530; http://dx.doi.org/10.1177/0748233711414608
   PubMed Web of Science ®Google Scholar
• Lord MJ, Jolliffe NA, Marsden CJ, Pateman CS, Smith DC, Spooner RA, Watson PD, Roberts LM. Ricin. Mechanisms of cytotoxicity. Toxicol Rev 2003; 22:53-64; PMID:14579547; http://dx.doi.org/10.2165/00139709-200322010-00006
   PubMedGoogle Scholar
• Audi J, Belson M, Patel M, Schier J, Osterloh J. Ricin poisoning: a comprehensive review. JAMA 2005; 294:2342-51; PMID:16278363; http://dx.doi.org/10.1001/jama.294.18.2342
   PubMed Web of Science ®Google Scholar
• Kende M, Yan C, Hewetson J, Frick MA, Rill WL, Tammariello R. Oral immunization of mice with ricin toxoid vaccine encapsulated in polymeric microspheres against aerosol challenge. Vaccine 2002; 20:1681-91; PMID:11858879; http://dx.doi.org/10.1016/S0264-410X(01)00484-4
   PubMed Web of Science ®Google Scholar
• Yan C, Rill WL, Malli R, Hewetson J, Naseem H, Tammariello R, Kende M. Intranasal stimulation of long-lasting immunity against aerosol ricin challenge with ricin toxoid vaccine encapsulated in polymeric microspheres. Vaccine 1996; 14:1031-8; PMID:8879098; http://dx.doi.org/10.1016/0264-410X(96)00063-1
   PubMed Web of Science ®Google Scholar
• Griffiths GD, Bailey SC, Hambrook JL, Keyte MP. Local and systemic responses against ricin toxin promoted by toxoid or peptide vaccines alone or in liposomal formulations. Vaccine 1998; 16:530-5; PMID:9491508; http://dx.doi.org/10.1016/S0264-410X(97)80007-2
   PubMed Web of Science ®Google Scholar
• O'Hara JM, Yermakova A, Mantis NJ. Immunity to ricin: fundamental insights into toxin-antibody interactions. Curr Top Microbiol Immunol 2012; 357:209-41; PMID:22113742
   PubMed Web of Science ®Google Scholar
• Smallshaw JE, Vitetta ES. Ricin vaccine development. Curr Top Microbiol Immunol 2012; 357:259-72; PMID:21805396
   PubMed Web of Science ®Google Scholar
• Smallshaw JE, Richardson JA, Pincus S, Schindler J, Vitetta ES. Preclinical toxicity and efficacy testing of RiVax, a recombinant protein vaccine against ricin. Vaccine 2005; 23:4775-84; PMID:15961194; http://dx.doi.org/10.1016/j.vaccine.2005.04.037
   PubMed Web of Science ®Google Scholar
• Smallshaw JE, Richardson JA, Vitetta ES. RiVax, a recombinant ricin subunit vaccine, protects mice against ricin delivered by gavage or aerosol. Vaccine 2007; 25:7459-69; PMID:17875350; http://dx.doi.org/10.1016/j.vaccine.2007.08.018
   PubMed Web of Science ®Google Scholar
• Marconescu PS, Smallshaw JE, Pop LM, Ruback SL, Vitetta ES. Intradermal administration of RiVax protects mice from mucosal and systemic ricin intoxication. Vaccine 2010; 28:5315-22; PMID:20562013; http://dx.doi.org/10.1016/j.vaccine.2010.05.045
   PubMed Web of Science ®Google Scholar
• Smallshaw JE, Firan A, Fulmer JR, Ruback SL, Ghetie V, Vitetta ES. A novel recombinant vaccine which protects mice against ricin intoxication. Vaccine 2002; 20:3422-7; PMID:12213413; http://dx.doi.org/10.1016/S0264-410X(02)00312-2
   PubMed Web of Science ®Google Scholar
• Vitetta ES, Smallshaw JE, Coleman E, Jafri H, Foster C, Munford R, Schindler J. A pilot clinical trial of a recombinant ricin vaccine in normal humans. Proc Natl Acad Sci U S A 2006; 103:2268-73; PMID:16461456; http://dx.doi.org/10.1073/pnas.0510893103
   PubMed Web of Science ®Google Scholar
• Vitetta ES, Smallshaw JE, Schindler J. Pilot phase IB clinical trial of an alhydrogel-adsorbed recombinant ricin vaccine. Clin Vaccine Immunol 2012; 19:1697-9; PMID:22914366; http://dx.doi.org/10.1128/CVI.00381-12
   PubMed Web of Science ®Google Scholar
• McLain DE, Lewis BS, Chapman JL, Wannemacher RW, Lindsey CY, Smith LA. Protective effect of two recombinant ricin subunit vaccines in the New Zealand white rabbit subjected to a lethal aerosolized ricin challenge: survival, immunological response, and histopathological findings. Toxicol Sci 2012; 126:72-83; PMID:21987460; http://dx.doi.org/10.1093/toxsci/kfr274
   PubMed Web of Science ®Google Scholar
• Carra JH, Wannemacher RW, Tammariello RF, Lindsey CY, Dinterman RE, Schokman RD, Smith LA. Improved formulation of a recombinant ricin A-chain vaccine increases its stability and effective antigenicity. Vaccine 2007; 25:4149-58; PMID:17408819; http://dx.doi.org/10.1016/j.vaccine.2007.03.011
   PubMed Web of Science ®Google Scholar
• Olson MA, Carra JH, Roxas-Duncan V, Wannemacher RW, Smith LA, Millard CB. Finding a new vaccine in the ricin protein fold. Protein Eng Des Sel 2004; 17:391-7; PMID:15187223; http://dx.doi.org/10.1093/protein/gzh043
   PubMed Web of Science ®Google Scholar
• McLain DE, Horn TL, Detrisac CJ, Lindsey CY, Smith LA. Progress in biological threat agent vaccine development: a repeat-dose toxicity study of a recombinant ricin toxin A-chain (rRTA) 1-33/44-198 vaccine (RVEc) in male and female New Zealand white rabbits. Int J Toxicol 2011; 30:143-52; PMID:21378370; http://dx.doi.org/10.1177/1091581810396730
   PubMed Web of Science ®Google Scholar
• McHugh CA, Tammariello RF, Millard CB, Carra JH. Improved stability of a protein vaccine through elimination of a partially unfolded state. Protein Sci 2004; 13:2736-43; PMID:15340172; http://dx.doi.org/10.1110/ps.04897904
   PubMed Web of Science ®Google Scholar
• Marsden CJ, Smith DC, Roberts LM, Lord JM. Ricin: current understanding and prospects for an antiricin vaccine. Expert Rev Vaccines 2005; 4:229-37; PMID:15889996; http://dx.doi.org/10.1586/14760584.4.2.229
   PubMed Web of Science ®Google Scholar
• Maddaloni M, Cooke C, Wilkinson R, Stout AV, Eng L, Pincus SH. Immunological characteristics associated with the protective efficacy of antibodies to ricin. J Immunol 2004; 172:6221-8; PMID:15128810; http://dx.doi.org/10.4049/jimmunol.172.10.6221
   PubMed Web of Science ®Google Scholar
• Olson MA. Ricin A-chain structural determinant for binding substrate analogues: a molecular dynamics simulation analysis. Proteins 1997; 27:80-95; PMID:9037714; http://dx.doi.org/10.1002/(SICI)1097-0134(199701)27:1%3c80::AID-PROT9%3e3.0.CO;2-R
   PubMed Web of Science ®Google Scholar
• Baluna R, Rizo J, Gordon BE, Ghetie V, Vitetta ES. Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. Proc Natl Acad Sci U S A 1999; 96:3957-62; PMID:10097145; http://dx.doi.org/10.1073/pnas.96.7.3957
   PubMed Web of Science ®Google Scholar
• Ready MP, Kim Y, Robertus JD. Site-directed mutagenesis of ricin A-chain and implications for the mechanism of action. Proteins 1991; 10:270-8; PMID:1881883; http://dx.doi.org/10.1002/prot.340100311
   PubMed Web of Science ®Google Scholar
• Castelletti D, Fracasso G, Righetti S, Tridente G, Schnell R, Engert A, Colombatti M. A dominant linear B-cell epitope of ricin A-chain is the target of a neutralizing antibody response in Hodgkin's lymphoma patients treated with an anti-CD25 immunotoxin. Clin Exp Immunol 2004; 136:365-72; PMID:15086403; http://dx.doi.org/10.1111/j.1365-2249.2004.02442.x
   PubMed Web of Science ®Google Scholar
• Tommasi M, Castelletti D, Pasti M, Fracasso G, Lorenzetti I, Sartoris S, Pera C, Ferrara GB, Tridente G, Colombatti M. Identification of ricin A-chain HLA class II-restricted epitopes by human T-cell clones. Clin Exp Immunol 2001; 125:391-400; PMID:11531946; http://dx.doi.org/10.1046/j.1365-2249.2001.01525.x
   PubMed Web of Science ®Google Scholar
• O'Hara JM, Neal LM, McCarthy EA, Kasten-Jolly JA, Brey RN 3rd, Mantis NJ. Folding domains within the ricin toxin A subunit as targets of protective antibodies. Vaccine 2010; 28:7035-46; PMID:20727394; http://dx.doi.org/10.1016/j.vaccine.2010.08.020
   PubMedGoogle Scholar
• O'Hara JM, Kasten-Jolly JC, Reynolds CE, Mantis NJ. Localization of non-linear neutralizing B cell epitopes on ricin toxin's enzymatic subunit (RTA). Immunol Lett 2014; 158:7-13; PMID:24269767; http://dx.doi.org/10.1016/j.imlet.2013.11.009
   PubMed Web of Science ®Google Scholar
• Li Q, Xin W, Gao S, Kang L, Wang J. A low-toxic site-directed mutant of Clostridium perfringens epsilon-toxin as a potential candidate vaccine against enterotoxemia. Hum Vaccin Immunother 2013; 9:2386-92; PMID:23835363
   PubMed Web of Science ®Google Scholar